Abstract
We present a systematic of the randomized, double-blind, placebo-controlled studies published in the scientific literature concerning the pharmacological treatment and complementary therapies of the painful peripheral neuropathy associated with the human acquired immunodeficiency virus (HIV), between January, 1996 and octubre, 2015. The analysis comprises 20 studies selected from a total of 219 articles located.
The 20 controlled studies selected included 2246 patients with HIV-associated distal sensory neuropathy (HIV-SN), characteristically painful, in the form of distal sensory polyneuropathy (DSP) or antiretroviral neuropathy (ATN).
The results of this revision show the efficacy of 8% capsaicin, smoked cannabis and recombinant human neural growth factor (rhNGF) in pain management of DSP. Lamotrigine and Acetyl-L carnitine are promising medications in the ATN of HIV patients. Notwithstanding, a search for new therapeutic strategies for the management of DSP and ATN is still necessary.
References
CORNBLATH DR, MCARTHUR JC. Predominantly sensory neuropathy patients with AIDS and AIDS-related complex. Neurology. 1988; 38(5):794-796.
SMYTH K, AFFANDI JS, MCARTHUR JC, BOWTELL-HARRIS C, MIJCH AM, WATSON K, ET AL. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med. 2007; 8(6):367-373.
THALER H, PORTENOY RK. The undertreatment of pain in ambulatory AIDS patients. Pain. 1996;65(2-3):243-249.
BREITBART W, PASSIK S, MCDONALD MV. Patient related barriers to pain management in ambulatory AIDS patients. Pain. 1998;76(5):9-16.
FRICH LM, BORGBJERG FM. Pain and pain treatment in AIDS patients: a longitudinal study. J Pain Symptom Manage. 2000;19(5):339-347.
VERMA S, ESTANISLAO L, MINTZ L. Controlling neuropathic pain in HIV. Curr Infect Dis Rep. 2004; 6(3):237- 242.
ELLIS RJ ROSARIO D, CLIFFORD DB, MCARTHUR JC, SIMPSON D, ALEXANDER T, ET AL. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: The charter study. Arch Neurol. 2010: 67(5):552-558.
MARITZ J, BENATAR M, DAVE JA, HARRISON TB, BADRI M, LEVITT NS, ET AL. HIV neuropathy in South Africans: Frequency, characteristics, and risk factors. Muscle Nerve. 2010; 41(5):599-606.
BELACHEW D, SCHALLER B, ZENEBE G. Distal symmetric polyneuropathy and toxic neuropathy in HIV patients. Ann Trop Med Public Health. 2010; 3(1):1-8.
PHILLIPS TJ, CHERRY CL, COX S, MARSHALL SJ, RICE AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: A systematic review and metaanalysis of randomised controlled trials. PLoS One. 2010; 5:e14433.
SIMPSON DM, DORFMAN D, OLNEY RK, MCKINLEY G. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology. 1996;47(5):1254-1259.
YOULE M, OSIO M. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med. 2007;8(4):241-250.
KEMPER CA, KENT G, BURTON S, DERESINSKI SC. Mexiletine for HIVinfected patients with painful peripheral neuropathy: a double-blind, placebocontrolled, crossover treatment trial. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19: (4)367-372.
SHLAY JC, CHALONER K, MAX MB, FLAWS B. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA. 1998;280(18):1590-1595.
KIEBURTZ K, SIMPSON D, YIANNOUTSOS C, MAX MB. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology. 1998;51(6):1682-1688.
NAVIA BA, DAFNI U, SIMPSON D, TUCKER T. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology. 1998;51:221-228.
SIMPSON DM, OLNEY R, MCARTHUR JC, KHAN A, GODBOLD J. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology. 2000;54(11):2115-2119.
Simpson DM, McArthur JC, Olney R, Clifford D, So Y. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo controlled trial. Neurology. 2003;60(9):1508-1514.
SILVER M, BLUM D, GRAINGER J, HAMMER AE, QUESSY S. Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage. 2007;34(4): 446-454.
MCARTHUR JC, YIANNOUTSOS C, SIMPSON DM, ADORNATO BT, SINGER EJ, ET AL. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology. 2000;54(5): 1080-1088.
PAICE JA, FERRANS CE, LASHLEY FR, SHOTT S, VIZGIRDA V, ET AL. Topical capsaicin in the management of HIV-associated peripheral neuropathy. J Pain Symptom Manage. 2000;19(1):45-52.
SIMPSON DM, BROWN S, TOBIAS J. NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70(24):2305-2313.
CLIFFORD D, SIMPSON D, BROWN S, MOYLE G, BREW B. A multicenter, randomized, double-blind, controlled study of NGX-4010 (QutenzaH), a high concentration capsaicin patch for the treatment of HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr. 2012;1;59(2):126-33.
HAHN K, ARENDT G, BRAUN JS, VON GIESEN HJ, HUSSTEDT IW, ET AL. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol. 2004; 251(10):1260-1266.
ESTANISLAO L, CARTER K, MCARTHUR J, OLNEY R, SIMPSON D. Lidoderm-HIV Neuropathy Group. A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr. 2004;37(5):1584-1586.
SCHIFITTO G, YIANNOUTSOS CT, SIMPSON DM, MARRA CM, SINGER EJ. A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J Neurovirol. 2006;12(4):328-331.
EVANS SR, SIMPSON DM, KITCH DW, KING A, CLIFFORD DB, ET AL. A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS one. 2007; 2:e551.
ABRAMS DI, JAY CA, SHADE SB, VIZOSO H, REDA H, ET AL. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515-521.
ELLIS RJ, TOPEROFF W, VAIDA F, VAN DEN BRANDE G, GONZALES J. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672-680.
SIMPSON DM, SCHIFITTO G, CLIFFORD DB, MURPHY TK, DURSO-DE, CRUZ E, ET AL. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology. 2010;74(5):413-420.
KESWANI SC, PARDO CA, CHERRY CL, HOKE A, MCARTHUR JC. HIV-associated sensory neuropathies. AIDS. 2002;16(16):2105-2117.
GONZALEZ-DUARTE A, ROBINSON-PAPP J, SIMPSON DM. Diagnosis and management of HIV-associated neuropathy. Neurol Clin. 2008;26:821- 832.
MOYLE G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther. 2000; 22(8):911-936; discussion 898.
CHILDS EA, LYLES RH, SELNES OD. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology.1999;52(3):607-613.
LEVI-MONTALCINI R, SKAPER SD, DAL TOSO R, PETRELLI L, LEON A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 1996;19(11):514-520.
PETERSEN KL, FIELDS HL, BRENNUM J, SANDRONI P, ROWBOTHAM MC. Capsaicin evoked pain and allodynia in post-herpetic neuralgia. Pain. 2000; 88: 125e133.
CORTRIGHT DN, SZALLASI A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem. 2004;271(10):1814e1819.
MOU J, PAILLARD F, TURNBULL B, TRUDEAU J. Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: A meta-analysis of the Qutenza Clinical Trials Database. Pain 2013;154(9):1632-9.
WALKER JM, HUANG SM. Cannabinoid analgesia. Pharmacol Ther. 2002; 95:127-135.
MILSTEIN SL, MACCANNELL K, KARR G, CLARK S. Cannabis-produced changes in pain tolerance. Experienced and non-experienced subjects. Int Pharmacopsychiatry. 1975;10(3):177-182.
HERZBERG U, ELIAV E, BENNETT GJ, KOPIN IJ. The analgesic effect of R (_)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett. 1997; 221:157-160.
BEAULIEU P, WARE M. Reassessment of the role of cannabinoids in the management of pain. Curr Opin Anaesthesiol. 2007;20(5):473-477.
FINNERUP NB, SINDRUP SH, JENSEN TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150(3):573-581.
DWORKIN RH, O'CONNOR AB, BACKONJA M, FARRAR JT, FINNERUP NB. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-251.
ATTAL N, CRUCCU G, BARON R, HAANPAA M, HANSSON P, JENSEN T, ET AL. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of neurology. 2010;17(9):1113-1123.
WIEBE L, PHILLIPS T, LI J. Pain in HIV: An Evolving Epidemic. The Journal of Pain. 2011;12(6): 619-624.
MILSTEIN SL, MACCANNELL K, KARR G, CLARK S. Cannabis-produced changes in pain tolerance. Experienced and non-experienced subjects. Int Pharmacopsychiatry. 1975;10(3):177-182.
ATTAL N, CRUCCU G, BARON R, HAANPAA M, HANSSON P, JENSEN T, ET AL. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-1123.
BARON R, TOLLE TR, GOCKEL U, BROSZ M, FREYNHAGEN R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain. 2009; 146(1-2):34-40.
SCHOLZ J, MANNION RJ, HORD DE, GRIFFIN RS, RAWAL B, ET AL. A novel tool for the assessment of pain: validation in low back pain. PLoS Med. 2009;6 e1000047.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.